Aptahem’s presentation at the BioStock Investor Meeting now available


Aptahem’s CEO Mikael Lindstam presented the company and gave an update on the ongoing activities at the BioStock Investor Meeting on 20 September 2023.

The presentation, which is held in English, and an interview, in Swedish, are now available at the company’s website:


For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.